Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition
- PMID: 20649976
- PMCID: PMC2917429
- DOI: 10.1186/1476-4598-9-196
Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition
Abstract
Background: ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments and most of them eventually relapse. The existence of this population of particularly aggressive and non-responding or relapsing patients urges the search for novel therapies. The purpose of this study was to determine whether cannabinoids might constitute a new therapeutic tool for the treatment of ErbB2-positive breast tumors. We analyzed their antitumor potential in a well established and clinically relevant model of ErbB2-driven metastatic breast cancer: the MMTV-neu mouse. We also analyzed the expression of cannabinoid targets in a series of 87 human breast tumors.
Results: Our results show that both Delta9-tetrahydrocannabinol, the most abundant and potent cannabinoid in marijuana, and JWH-133, a non-psychotropic CB2 receptor-selective agonist, reduce tumor growth, tumor number, and the amount/severity of lung metastases in MMTV-neu mice. Histological analyses of the tumors revealed that cannabinoids inhibit cancer cell proliferation, induce cancer cell apoptosis, and impair tumor angiogenesis. Cannabinoid antitumoral action relies, at least partially, on the inhibition of the pro-tumorigenic Akt pathway. We also found that 91% of ErbB2-positive tumors express the non-psychotropic cannabinoid receptor CB2.
Conclusions: Taken together, these results provide a strong preclinical evidence for the use of cannabinoid-based therapies for the management of ErbB2-positive breast cancer.
Figures
Similar articles
-
Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.Mol Cancer Ther. 2009 Nov;8(11):3117-29. doi: 10.1158/1535-7163.MCT-09-0448. Epub 2009 Nov 3. Mol Cancer Ther. 2009. PMID: 19887554 Free PMC article.
-
Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6143-56. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26261492 Free PMC article.
-
CB2 cannabinoid receptor activation promotes colon cancer progression via AKT/GSK3β signaling pathway.Oncotarget. 2016 Oct 18;7(42):68781-68791. doi: 10.18632/oncotarget.11968. Oncotarget. 2016. PMID: 27634891 Free PMC article.
-
The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.J Neuroimmune Pharmacol. 2015 Jun;10(2):255-67. doi: 10.1007/s11481-015-9608-y. Epub 2015 Apr 28. J Neuroimmune Pharmacol. 2015. PMID: 25916739 Free PMC article. Review.
-
Cannabinoids and the skeleton: from marijuana to reversal of bone loss.Ann Med. 2009;41(8):560-7. doi: 10.1080/07853890903121025. Ann Med. 2009. PMID: 19634029 Review.
Cited by
-
Cannabis and cancer: unveiling the potential of a green ally in breast, colorectal, and prostate cancer.J Cannabis Res. 2024 May 16;6(1):24. doi: 10.1186/s42238-024-00233-z. J Cannabis Res. 2024. PMID: 38755733 Free PMC article. Review.
-
Effects of Cannabidiol, ∆9-Tetrahydrocannabinol, and WIN 55-212-22 on the Viability of Canine and Human Non-Hodgkin Lymphoma Cell Lines.Biomolecules. 2024 Apr 19;14(4):495. doi: 10.3390/biom14040495. Biomolecules. 2024. PMID: 38672512 Free PMC article.
-
Chemistry and Pharmacology of Delta-8-Tetrahydrocannabinol.Molecules. 2024 Mar 11;29(6):1249. doi: 10.3390/molecules29061249. Molecules. 2024. PMID: 38542886 Free PMC article. Review.
-
Could cannabinoids provide a new hope for ovarian cancer patients?Pharmacol Res Perspect. 2023 Aug;11(4):e01122. doi: 10.1002/prp2.1122. Pharmacol Res Perspect. 2023. PMID: 37526235 Free PMC article. Review.
-
Should oncologists trust cannabinoids?Front Pharmacol. 2023 Jul 13;14:1211506. doi: 10.3389/fphar.2023.1211506. eCollection 2023. Front Pharmacol. 2023. PMID: 37521486 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
